.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,641,843

« Back to Dashboard

Claims for Patent: 6,641,843

Title: Pharmaceutical compositions
Abstract:The present invention relates to pharmaceutical compostions of (1S,4R)-cis-4-[2-amino-6-cyclopropylamino}-9H-purin-9-yl]-2-cyclopentene-1 -methanol (1592U89).
Inventor(s): Brooks; Nikki Thoennes (Glen Allen, VA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:09/601,671
Patent Claims: 1. A pharmaceutical composition for oral administration comprising (1S,4R)-cis-4-[(2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol, or a pharmaceutically acceptable derivative thereof, together with citrate and at least one sweetener selected from sorbitol and saccharin, at a pH range of 2.0 to 4.5.

2. A pharmaceutical composition for oral administration comprising (1S,4R)-cis-4-[(2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol, or a pharmaceutically acceptable derivative thereof, together with citrate and at least one sweetener selected from sorbitol and saccharin, at a pH range of 6.6 to 7.5.

3. A pharmaceutical composition as claimed in claim 1 wherein the sweetener is saccharin and the composition further comprises fructose and acesulfame.

4. A pharmaceutical composition as claimed in claim 2 wherein the sweetener is saccharin and the composition further comprises fructose and acesulfame.

5. A pharmaceutical composition as claimed in claim 1 wherein the pharmaceutically acceptable derivative of (1S,4R)-cis-4-[(2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol is the hemisulfate salt.

6. A process for formulating (1S,4R)-cis-4-[(2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol for oral administration comprising the step of bringing (1S,4R)-cis-4-[(2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol, or a pharmaceutically acceptable derivative thereof, into association with citrate and a sweetening agent which does not contain a carboxyl group.

7. A process as claimed in claim 6 wherein the (1S,4R)-cis-4-[(2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol is in the form of its hemisulfate salt.

8. A pharmaceutical composition for oral administration comprising (1S,4R)-cis-4-[2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1 -methanol, or a pharmaceutically acceptable derivative thereof, citrate, and a sweetening agent compatible with said (1S,4R)-cis-4-[2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1 -methanol, or pharmaceutically acceptable derivative thereof.

9. A pharmaceutical composition as claimed in claim 8 at a pH range of 2.0 to 4.5.

10. A pharmaceutical composition according to claim 9 wherein the pH range is 3.8.

11. A pharmaceutical composition according to claim 10 wherein the pH is 4.1.

12. A pharmaceutical composition as claimed in claim 8 wherein the sweetening agent is selected from the group consisting of sorbitol, saccharin, acesulfame, fructose, sucralose, and aspartame.

13. A pharmaceutical composition according to claim 8 wherein the citrate ion concentration is in the range of 0.01 M to 0.1 M.

14. A pharmaceutical composition according to claim 1 in the form of a solution.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc